- Home
- KOD vs DHY Comparison
KOD vs DHY Comparison
Compare KOD & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- DHY
- Stock Information
- Founded
- KOD 2009
- DHY 1998
- Country
- KOD United States
- DHY United States
- Employees
- KOD N/A
- DHY N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- DHY Finance/Investors Services
- Sector
- KOD Health Care
- DHY Finance
- Exchange
- KOD Nasdaq
- DHY Nasdaq
- Market Cap
- KOD 198.4M
- DHY 220.7M
- IPO Year
- KOD 2018
- DHY N/A
- Fundamental
- Price
- KOD $10.52
- DHY $2.09
- Analyst Decision
- KOD Hold
- DHY
- Analyst Count
- KOD 4
- DHY 0
- Target Price
- KOD $11.75
- DHY N/A
- AVG Volume (30 Days)
- KOD 673.8K
- DHY 569.1K
- Earning Date
- KOD 08-13-2025
- DHY 01-01-0001
- Dividend Yield
- KOD N/A
- DHY 9.10%
- EPS Growth
- KOD N/A
- DHY N/A
- EPS
- KOD N/A
- DHY N/A
- Revenue
- KOD N/A
- DHY N/A
- Revenue This Year
- KOD N/A
- DHY N/A
- Revenue Next Year
- KOD N/A
- DHY N/A
- P/E Ratio
- KOD N/A
- DHY N/A
- Revenue Growth
- KOD N/A
- DHY N/A
- 52 Week Low
- KOD $1.92
- DHY $1.77
- 52 Week High
- KOD $11.60
- DHY $2.08
- Technical
- Relative Strength Index (RSI)
- KOD 64.28
- DHY 43.42
- Support Level
- KOD $8.29
- DHY $2.07
- Resistance Level
- KOD $9.23
- DHY $2.11
- Average True Range (ATR)
- KOD 0.98
- DHY 0.02
- MACD
- KOD -0.16
- DHY 0.00
- Stochastic Oscillator
- KOD 74.33
- DHY 50.00
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.